BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37097698)

  • 1. Liver Metastases of Unknown Primary Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors: A Case Report and Literature Review.
    Bimbatti D; Cavasin N; Galuppini F; Rago A; Ramondo G; Lai E; Dionese M; Erbetta E; Basso U; Maruzzo M
    Anticancer Res; 2023 May; 43(5):2359-2365. PubMed ID: 37097698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
    Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
    Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Immunotherapy and Tyrosine Kinase Inhibitor Treatment for Metastatic Renal Cell Carcinoma With Unknown Primary Origin: A Report of Two Cases and Literature Review.
    Chen HX; Yu LT; Chang H; Huang WH; Lin WC; Chang CH
    In Vivo; 2023; 37(4):1905-1913. PubMed ID: 37369518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.
    Sekino Y; Teishima J; Liang G; Hinata N
    Int J Urol; 2022 Dec; 29(12):1419-1428. PubMed ID: 36122306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
    Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
    Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
    Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
    Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
    Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
    Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
    Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
    Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
    [No Abstract]   [Full Text] [Related]  

  • 14. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
    Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Horimoto T; Nakai M; Kadono Y; Nojima T; Tsuchiya H
    Front Immunol; 2022; 13():980456. PubMed ID: 36238308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Hara T; Miyake H; Fujisawa M
    Urol Oncol; 2017 Jun; 35(6):363-369. PubMed ID: 28169111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testicular metastasis from renal cell carcinoma after nephrectomy and on tyrosine kinase inhibitors therapy: Case report and review.
    De Gobbi A; Mangano MS; Cova G; Lamon C; Maccatrozzo L
    Urologia; 2019 May; 86(2):96-98. PubMed ID: 30706765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma.
    Bersanelli M; Buti S; Rizzo M
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):401-412. PubMed ID: 33287612
    [No Abstract]   [Full Text] [Related]  

  • 19. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
    Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
    Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.